1.4121
0.15%
+0.0021
After Hours:
1.4121
Exagen Inc stock is currently priced at $1.4121, with a 24-hour trading volume of 3,511.
It has seen a +0.15% increased in the last 24 hours and a -8.31% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $1.39 pivot point. If it approaches the $1.43 resistance level, significant changes may occur.
Previous Close:
$1.41
Open:
$1.41
24h Volume:
3,511
Market Cap:
$24.34M
Revenue:
$52.55M
Net Income/Loss:
$-23.69M
P/E Ratio:
-0.6991
EPS:
-2.02
Net Cash Flow:
$-15.29M
1W Performance:
+3.07%
1M Performance:
-8.31%
6M Performance:
-9.48%
1Y Performance:
-44.41%
Exagen Inc Stock (XGN) Company Profile
Name
Exagen Inc
Sector
Industry
Phone
760 560 1501
Address
1261 Liberty Way, Vista, CA
Exagen Inc Stock (XGN) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Aug-05-22 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
Oct-15-21 | Resumed | Cowen | Outperform |
Apr-15-21 | Initiated | Canaccord Genuity | Buy |
Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
Oct-08-20 | Initiated | BTIG Research | Buy |
Jun-02-20 | Resumed | Cantor Fitzgerald | Overweight |
Oct-14-19 | Initiated | Cantor Fitzgerald | Overweight |
Oct-14-19 | Initiated | Cowen | Outperform |
Oct-14-19 | Initiated | William Blair | Outperform |
View All
Exagen Inc Stock (XGN) Latest News
Exagen Inc. Announces Changes to the Board of Directors
GlobeNewswire Inc.
Exagen Inc. (XGN) Reports Q4 Loss, Tops Revenue Estimates
Zacks Investment Research
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results
GlobeNewswire Inc.
Cresco Labs Inc. (CRLBF) Q4 Earnings and Revenues Surpass Estimates
Zacks Investment Research
Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
GlobeNewswire Inc.
Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024
GlobeNewswire Inc.
Exagen Inc Stock (XGN) Financials Data
Exagen Inc (XGN) Revenue 2024
XGN reported a revenue (TTM) of $52.55 million for the quarter ending December 31, 2023, a +15.33% rise year-over-year.
Exagen Inc (XGN) Net Income 2024
XGN net income (TTM) was -$23.69 million for the quarter ending December 31, 2023, a +50.01% increase year-over-year.
Exagen Inc (XGN) Cash Flow 2024
XGN recorded a free cash flow (TTM) of -$15.29 million for the quarter ending December 31, 2023, a +58.07% increase year-over-year.
Exagen Inc (XGN) Earnings per Share 2024
XGN earnings per share (TTM) was -$1.34 for the quarter ending December 31, 2023, a +51.45% growth year-over-year.
About Exagen Inc
Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody and associated vasculitis; AVISE Anti-CarP test, which identifies RA patients with severe disease; and AVISE PC4d to measure platelet- bound C4d. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine. It has a research collaboration and license agreement with Allegheny Health Network (AHN) Research Institute to develop novel patented biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Cap:
|
Volume (24h):